NDA 021152 · Fougera
Cutivate
Fluticasone Propionate · Topical
DiscontinuedLast checked: Nov 20, 2026Latest source record: Jan 16, 2015 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2005
Mar 31, 2005
Approved uses
2
Original approval plus efficacy supplements
Registered trials
738
240 Phase 3, 19 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 16, 2015 Supplement 4 · Efficacy LetterPediatric Medical ReviewPediatric Clinical Pharmacology Review
- Mar 31, 2005 Original approval · Type 3 - New Dosage Form ReviewLetter
1 products under this application
- CUTIVATE · FLUTICASONE PROPIONATE 0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · LOTION, TOPICAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Fluticasone Propionate" as an intervention, any sponsor and status, largest first.
- Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary DiseasePivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT01313676 · 16,568 participants · Start Jan 25, 2011 · Primary completion Jul 15, 2015
Drug: fluticasone furoate/vilanterol; fluticasone furoate and 1 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Andalusia, Alabama; Athens, Alabama; Birmingham, Alabama · 1,611 sites in all
GlaxoSmithKlineGSK (GSK)
NCT01475721 · 11,751 participants · Start Nov 18, 2011 · Primary completion Jun 23, 2015
Drug: ADVAIR 100/50mcg; ADVAIR 250/50mcg and 4 more · For: Asthma
Sites: Athens, Alabama; Birmingham, Alabama; Florence, Alabama · 808 sites in all
- ACTIV-6: COVID-19 Study of Repurposed MedicationsPivotal-lookingCompleted
Susanna Naggie, MDAcademic, hospital or other
NCT04885530 · 10,956 participants · Start Jun 8, 2021 · Primary completion Apr 29, 2024
Drug: Ivermectin; Fluvoxamine and 3 more · For: Covid19
Sites: Chandler, Arizona; Gilbert, Arizona; Mesa, Arizona · 110 sites in all
GlaxoSmithKlineGSK (GSK)
NCT02164513 · 10,355 participants · Start Jun 30, 2014 · Primary completion Jul 17, 2017
Drug: fluticasone furoate (FF); vilanterol (VI) and 1 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Athens, Alabama; Birmingham, Alabama; Florence, Alabama · 998 sites in all
- 6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years OldPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT01462344 · 6,250 participants · Start Nov 17, 2011 · Primary completion Nov 1, 2015
Drug: ADVAIR 100/50mcg; ADVAIR 250/50mcg and 2 more · For: Asthma
Sites: Birmingham, Alabama; Mobile, Alabama; Montgomery, Alabama · 530 sites in all
- Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)Pivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT00268216 · 6,228 participants · Start Sep 2000 · Primary completion Nov 2005
Drug: Salmeterol 50mcg/ Fluticasone Propionate 500mcg · For: Pulmonary Disease, Chronic Obstructive
Sites: Birmingham, Alabama; Jasper, Alabama; Mobile, Alabama · 459 sites in all
- An Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in AsthmaPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT01706198 · 4,233 participants · Start Nov 1, 2012 · Primary completion Dec 1, 2016
Drug: fluticasone furoate + vilanterol; inhaled corticosteroid with or without a long acting beta2-agonist · For: Asthma
Sites: Altrincham, United Kingdom; Bowdon, United Kingdom; Cheadle, United Kingdom · 180 sites in all
- QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study, FLAME (EFfect of Indacaterol Glycopyronium Vs Fluticasone Salmeterol on COPD Exacerbations)Pivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01782326 · 3,362 participants · Start Jul 2013 · Primary completion Sep 2015
Drug: QVA149; Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS) · For: Chronic Obstructive Pulmonary Disease (COPD)
Sites: Ciudad de Buenos Aires, Argentina; Buenos Aires, Argentina; Caba, Argentina · 499 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Intranasal antihistamines and corticosteroids in allergic rhinitis: A systematic review and meta-analysis.
Sousa-Pinto B, Vieira RJ, Brozek J, et al. · J Allergy Clin Immunol 2024 · Systematic Review, Meta-Analysis
- Oral steroid-sparing effect of high-dose inhaled corticosteroids in asthma.
Maijers I, Kearns N, Harper J, et al. · Eur Respir J 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis.
Lipworth BJ · Arch Intern Med 1999 · Meta-Analysis, Systematic Review
- Fluticasone Propionate Orally Disintegrating Tablet (APT-1011) for Eosinophilic Esophagitis: Randomized Controlled Trial.
Dellon ES, Lucendo AJ, Schlag C, et al. · Clin Gastroenterol Hepatol 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Pharmacokinetic Models for Inhaled Fluticasone Propionate and Salmeterol Xinafoate to Quantify Batch-to-Batch Variability.
Li S, Feng K, Lee J, et al. · AAPS J 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Quantitative comparison of dose-effect and time-course of fluticasone furoate and fluticasone propionate in adult and adolescent patients with persistent asthma: A systematic review and meta-analysis.
Zhong Y, Li L, Chen R, et al. · Respirology 2022 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Fougera
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.